Notaflu Lemon Oil Nasal
NDC Package 78527-003-01
Package Information
Notaflu Lemon Oil Nasal is a . Marketed by Rapha Health Network International, this product is identified by NDC 78527-003.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 78527 - Rapha Health Network International
- 78527-003 - Notaflu Lemon Oil Nasal
- 78527-003-01 - 30 mL in 1 BOTTLE, SPRAY
- 78527-003 - Notaflu Lemon Oil Nasal
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 78527-003-01 identifies a specific commercial package of 30 ml in 1 bottle, spray of Notaflu Lemon Oil Nasal, labeled by Rapha Health Network International. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rapha Health Network International on September 16, 2013. The current certification is valid through September 17, 2024.
How is this Rapha Health Network International product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 78527000301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.